Ardelyx (ARDX)

• Market cap: $1.36B
• 1 day: -3.66%
• 5 days: -12.66%
• 1 month: -24.38%
• 3 months: -14.68%
• 6 months: -0.36%
• Year to date: -10.24%
• 1 year: 43.38%
• 5 years: -20%
• 10 years: -40.45%
• Sector: Healthcare
• Industry: Biotechnology

About: Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Employees: 489